NASDAQ:CDXS Codexis (CDXS) Stock Price, News & Analysis $2.32 +0.02 (+0.87%) Closing price 05/1/2025 04:00 PM EasternExtended Trading$2.32 0.00 (-0.22%) As of 05/1/2025 05:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Codexis Stock (NASDAQ:CDXS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Codexis alerts:Sign Up Key Stats Today's Range$2.27▼$2.4050-Day Range$1.97▼$4.1652-Week Range$1.90▼$6.08Volume471,822 shsAverage Volume661,050 shsMarket Capitalization$192.18 millionP/E RatioN/ADividend YieldN/APrice Target$8.33Consensus RatingModerate Buy Company OverviewCodexis, Inc. discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used for molecular biology and in vitro diagnostic enzymes. It has a collaboration agreement with Nestlé Health Science to develop CDX-7108 for the treatment of exocrine pancreatic insufficiency. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.Read More… Codexis Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks70th Percentile Overall ScoreCDXS MarketRank™: Codexis scored higher than 70% of companies evaluated by MarketBeat, and ranked 336th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingModerate Buy Consensus RatingCodexis has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageCodexis has received no research coverage in the past 90 days.Read more about Codexis' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Codexis are expected to grow in the coming year, from ($0.77) to ($0.66) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Codexis is -2.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Codexis is -2.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCodexis has a P/B Ratio of 1.87. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Codexis' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.73% of the float of Codexis has been sold short.Short Interest Ratio / Days to CoverCodexis has a short interest ratio ("days to cover") of 6.Change versus previous monthShort interest in Codexis has recently increased by 4.89%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCodexis does not currently pay a dividend.Dividend GrowthCodexis does not have a long track record of dividend growth. Sustainability and ESG2.5 / 5Environmental Score-3.67 Percentage of Shares Shorted6.73% of the float of Codexis has been sold short.Short Interest Ratio / Days to CoverCodexis has a short interest ratio ("days to cover") of 6.Change versus previous monthShort interest in Codexis has recently increased by 4.89%, indicating that investor sentiment is decreasing. News and Social Media3.4 / 5News Sentiment1.08 News SentimentCodexis has a news sentiment score of 1.08. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.84 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Codexis this week, compared to 3 articles on an average week.MarketBeat Follows2 people have added Codexis to their MarketBeat watchlist in the last 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Codexis insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.10% of the stock of Codexis is held by insiders.Percentage Held by Institutions78.54% of the stock of Codexis is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Codexis' insider trading history. Receive CDXS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Codexis and its competitors with MarketBeat's FREE daily newsletter. Email Address CDXS Stock News HeadlinesCodexis to Report First Quarter 2025 Financial Results on May 14April 30 at 4:15 PM | globenewswire.comCodexis (CDXS) Projected to Post Quarterly Earnings on ThursdayApril 29 at 3:47 AM | americanbankingnews.comTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.May 2, 2025 | Porter & Company (Ad)Major Investment Alert: Opaleye Management Inc. Boosts Stake in Codexis!April 9, 2025 | tipranks.comCodexis Announces Board Member Retirement in April 2025April 9, 2025 | tipranks.comCodexis Announces Byron Dorgan to Retire from Board of DirectorsApril 9, 2025 | globenewswire.comCodexis Announces Byron Dorgan to Retire from Board of DirectorsApril 9, 2025 | globenewswire.comCodexis shares bought by Opaleye Management for $198,380April 9, 2025 | investing.comSee More Headlines CDXS Stock Analysis - Frequently Asked Questions How have CDXS shares performed this year? Codexis' stock was trading at $4.77 on January 1st, 2025. Since then, CDXS shares have decreased by 51.4% and is now trading at $2.32. View the best growth stocks for 2025 here. How were Codexis' earnings last quarter? Codexis, Inc. (NASDAQ:CDXS) posted its earnings results on Thursday, February, 27th. The biotechnology company reported ($0.13) earnings per share for the quarter, missing analysts' consensus estimates of ($0.04) by $0.09. The biotechnology company had revenue of $21.46 million for the quarter, compared to analyst estimates of $27.41 million. Codexis had a negative net margin of 96.35% and a negative trailing twelve-month return on equity of 71.56%. Read the conference call transcript. Who are Codexis' major shareholders? Top institutional investors of Codexis include Assenagon Asset Management S.A. (0.73%), Post Resch Tallon Group Inc. (0.57%), Envestnet Asset Management Inc. (0.46%) and Rhumbline Advisers (0.13%). Insiders that own company stock include Opaleye Management Inc, John J Nicols, Byron L Dorgan, Sriram Ryali, Kevin Norrett and Margaret Nell Fitzgerald. View institutional ownership trends. How do I buy shares of Codexis? Shares of CDXS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Codexis own? Based on aggregate information from My MarketBeat watchlists, some other companies that Codexis investors own include Tesla (TSLA), NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Netflix (NFLX), Walt Disney (DIS) and JPMorgan Chase & Co. (JPM). Company Calendar Last Earnings2/27/2025Today5/01/2025Next Earnings (Estimated)5/01/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Industrial organic chemicals Sub-IndustryBiotechnology Current SymbolNASDAQ:CDXS CIK1200375 Webwww.codexis.com Phone(650) 421-8100Fax650-421-8102Employees250Year FoundedN/APrice Target and Rating Average Stock Price Target$8.33 High Stock Price Target$11.00 Low Stock Price Target$5.00 Potential Upside/Downside+259.2%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.90) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-76,240,000.00 Net Margins-96.35% Pretax Margin-96.25% Return on Equity-71.56% Return on Assets-38.00% Debt Debt-to-Equity Ratio0.39 Current Ratio3.21 Quick Ratio3.15 Sales & Book Value Annual Sales$59.35 million Price / Sales3.24 Cash FlowN/A Price / Cash FlowN/A Book Value$1.24 per share Price / Book1.87Miscellaneous Outstanding Shares82,837,000Free Float79,669,000Market Cap$192.18 million OptionableOptionable Beta2.35 These 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:CDXS) was last updated on 5/2/2025 by MarketBeat.com Staff From Our PartnersThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredTrump Orders 'National Digital Asset Stockpile'Billionaires Rush Into Digital Banking Token Three massive forces are converging right now, creating what c...Crypto 101 Media | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Codexis, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Codexis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.